GE Healthcare is partnering with the National Multiple Sclerosis Society to fund a clinical trial evaluating the use of GE180, GE's investigational PET imaging agent, in multiple sclerosis patients. The trial is meant to determine whether evaluating MS patients for neuroinflammation -- using PET with GE180 -- before and after natalizumab therapy can pinpoint patients who might benefit from the treatment.

Related Summaries